News from AAN 2026: BTKi
At the end of April, the annual meeting of the American Academy of Neurology (AAN) took place in Chicago. I had the opportunity to attend the congress on site and therefore want to summarize some
Continue reading
Category: General
ACTRIMS 2026: Ublituximab, Vidofludimus Calcium & GA Depot
Ublituximab in children, Vidofludimus Calcium in progression, Glatirameracetat in PPMS? All three were a topic at the ACTRIMS Congress in February 2026. Prof. Mathias Mäurer talks about the three active substances in this video. And
Continue reading
New Year, new on BTKi: PERSEUS Study misses the primary endpoint
First of all, I would like to wish all readers of MS-DocBlog a happy and successful new year. – Stay healthy and hopeful, despite all adversities. Speaking of adversities – this brings us right back
Continue reading
Merry Christmas and a Happy New Year 2026
The year 2025 was not an easy year. It was characterized by intense political, economic and social developments. The war in Ukraine, the Gaza crisis, geopolitical tensions, but also domestic political disputes kept us on
Continue reading
BTKi – the direction is right.
On November 10, 2025, Roche released a press release announcing that Fenebrutinib has reached its primary endpoint in the first Phase III trial (FENhance 2) of two similarly designed pivotal Phase III trials (FENhance 1
Continue reading
News from ECTRIMS 2025 (1)
Those who have been with DocBlog for a while know: autumn is congress time. As always at this time, the world’s largest MS meeting took place again this year – almost 10,000 MS experts from
Continue readingNew LMU Munich Study on the Importance of the Microbiome in MS
The connection between autoimmune inflammation and the gut microbiome has sparked great interest in the MS community in recent years. There is now interesting news on this topic: The Institute for Clinical Neuroimmunology at the
Continue reading
MS Topics at Neurologist Congress AAN 2025
The annual meeting of the American Academy of Neurology (AAN) is the largest neurological congress worldwide and covers all sub-areas of neurology. The AAN is not necessarily the most important meeting for the discussion of
Continue readingAI in Medicine – (Not) a Fear-Driven Topic
When one looks at the progress made in “large language models” such as ChatGPT, one cannot help but be amazed. Questions from all areas of life are answered reliably and linguistically sophisticated within seconds. Even
Continue readingNew Findings on BTKi – the Tolebrutinib Study Program
At this year’s ECTRIMS Meeting in Copenhagen, the data from the study program of the Bruton-Tyrosine-Kinase (BTK) inhibitor Tolebrutinib was presented. And what can I say – fortunately there were positive news this time.
Continue reading
